Evelo Therapeutics Expands to New Headquarters in Cambridge
Cambridge, Mass. - December 18, 2015
Cambridge, MA – December 18, 2015 – Evelo Therapeutics, a biotech company pioneering the development of microbiome-based therapies for cancer, today announced the official opening of its new 9,000 square foot headquarters in Cambridge, Massachusetts. The company emerged from Flagship VentureLabs®, the innovation foundry of Flagship Ventures, with an initial capital commitment of $35 million in November 2015. The ribbon-cutting ceremony was held yesterday afternoon in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio.
“I congratulate Evelo Therapeutics on their expansion and look forward to their continued contributions to job creation and innovation here in the Commonwealth,” said Governor Charlie Baker.
“We are extremely pleased with our new facility and the opportunity that it affords Evelo during this important growth period,” said Dr. Simba Gill, CEO of Evelo. “Cambridge is the undisputed hub of great biotech companies and we are excited to contribute to its legacy of innovative science and transformative medicine.”
The 9,000 square foot headquarters features a state-of-the-art laboratory space and office designed to foster collaboration. At this site, Evelo will continue to advance its research platform, based on a deep understanding of the cancer microbiome, and develop its Oncobiotic™ therapeutics as a new modality in cancer treatment.
“We are pleased to celebrate the grand opening of Evelo’s new headquarters in Cambridge,” said Travis McCready, President & CEO of the Massachusetts Life Sciences Center. “This new facility will allow the company to continue to grow and make important contributions to cancer therapeutics, one of the core strengths of our Commonwealth’s life sciences ecosystem.”
“We congratulate MassBio member Evelo Therapeutics on the grand opening of their exciting new headquarters in Cambridge, MA,” said Robert K. Coughlin, President & CEO of MassBio. “We are thrilled to see Evelo Therapeutics’ growth and know they will continue to thrive in Massachusetts’ robust oncology research and development community.”
About Evelo Therapeutics
Evelo Therapeutics is dedicated to transforming cancer therapy through a deep understanding of the cancer microbiome. Evelo is discovering and developing Oncobiotic™ therapies, novel treatments designed to attack cancer by disrupting the microbial environment that supports tumors and protects them from the body’s immune system. Evelo’s platform disrupts the tumor microenvironment at the metabolic and stromal levels and provides next-generation, microbiome-based immunotherapeutics. Founded at Flagship VentureLabs, Evelo is the first microbiome company focused on cancer. For more information, please visit www.evelotx.com.
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.
About Flagship VentureLabs®
Flagship VentureLabs is the innovation foundry of Flagship Ventures. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs has used its unique, systematic approach to produce first-in-class companies based on in-house innovations. Since its founding in 2000, the VentureLabs team has founded more than 35 life science companies, including Joule Unlimited, Seres Therapeutics, Pronutria Biosciences, Symbiota and Moderna Therapeutics. For more information, please visit www.flagshipventures.com/venturelabs.